Cardlytics (MEX:CDLX) YoY EBITDA Growth: -152.91% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:CDLX Cardlytics Inc MEX:CDLX
30 GF Score
Price MXN1,074.00
GF Value MXN3,778.99
! 5 Warning Signs
View Full Analysis

What is Cardlytics YoY EBITDA Growth?

Cardlytics MEX:CDLX 30 YoY EBITDA Growth is -152.91% as of Jun. 2026. GuruFocus rates MEX:CDLX with a GF Score™ of 30/100 and a GF Value™ of MXN3,778.99. The stock has 5 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Cardlytics's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was -152.91%.

Cardlytics's EBITDA per Share for the three months ended in Jun. 2026 was MXN-6.09.

Cardlytics YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Cardlytics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardlytics YoY EBITDA Growth Chart

Cardlytics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -88.50 -336.41 81.22 -42.84 66.27

Cardlytics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -41.07 59.57 115.71 -433.13 -152.91
MEX:CDLX
30GF Score
Cardlytics Inc MEX:CDLX
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardlytics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Cardlytics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-221.889--657.778)/ | -657.778 |
=66.27 %

Cardlytics's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-6.087-11.505)/ | 11.505 |
=-152.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -152.91% mean?
Cardlytics (MEX:CDLX) has a YoY EBITDA Growth of -152.91% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Cardlytics and its competitors.
Is Cardlytics' YoY EBITDA Growth too high?
Cardlytics' current YoY EBITDA Growth is -152.91%. Overall, Cardlytics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Cardlytics' YoY EBITDA Growth compare to WIMI and ACCS?
Cardlytics' YoY EBITDA Growth of -152.91% can be compared against companies in the Media - Diversified industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Media - Diversified company?
A good YoY EBITDA Growth depends on the Media - Diversified industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Cardlytics and its competitors. Cardlytics's current YoY EBITDA Growth is -152.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardlytics stock overvalued right now?
Cardlytics (MEX:CDLX) has a current YoY EBITDA Growth of -152.91%. The stock's GF Value™ is MXN3,778.99, compared to a current price of MXN1,074.00 — trading 71.6% below its estimated fair value. The current YoY EBITDA Growth is -152.91%. Cardlytics' overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Cardlytics (MEX:CDLX), the current YoY EBITDA Growth is -152.91% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cardlytics (MEX:CDLX) Overvalued in 2026?

Based on GuruFocus' analysis, Cardlytics stock appears to be undervalued. The current stock price of MXN1,074.00 is trading 71.6% below its estimated GF Value™ of MXN3,778.99.

Key valuation signals for MEX:CDLX:

  • YoY EBITDA Growth: -152.91%
  • GF Value™: MXN3,778.99 vs. price of MXN1,074.00 (71.6% below fair value)
  • GF Score™: 30/100 with 5 warning signs

No single metric tells the full story. See the MEX:CDLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cardlytics Business Description

Other Exchanges CDLX:USA0LEC:UKCYX0:Germany
Address 675 Ponce de Leon Avenue, NE, Suite 4100, Atlanta, GA, USA, 30308
Cardlytics Inc is a commerce media platform that is designed to make commerce smarter and rewarding for everyone. At the core of its commerce media platform is the financial media network that it runs within its partners' digital channels, which includes online and mobile applications (the Cardlytics platform). Additionally, it operates an identity resolution platform that utilizes point-of-sale (POS) data, including product-level purchase data, to enable marketers to perform analytics and targeted loyalty marketing and also measure the impact of their marketing (the Bridg platform). It operates in three segments: the Cardlytics platform in the U.S.; the Cardlytics platform in the U.K.; and the Bridg platform. The majority of the revenue is derived from the Cardlytics platform.
30GF Score

Get the complete analysis for MEX:CDLX

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,074.00
Price
MXN3,778.99
GF Value